Direct inhibition by a statin of TNFalpha-induced leukocyte recruitment in rat pial venules - in vivo confocal microscopic study

Pathophysiology : the Official Journal of the International Society for Pathophysiology
Ruriko ObamaYukito Shinohara

Abstract

3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) have been shown to block leukocyte-endothelial interaction independently of their cholesterol-lowering properties. The effects of statins are generally attributed to a decrease in mevalonate caused by inhibition of HMG-CoA reductase, which results in an increase of nitric oxide (NO). However, a recent in vitro study demonstrated a novel effect which depended on the lipophilicity of statin and appeared to be unrelated to HMG-CoA reductase inhibition. The purpose of this study is to investigate whether the proposed mechanism actually operates in vivo. We examined the effects of simvastatin (lipophilic) and pravastatin (hydrophilic) on leukocyte behavior in a tumor necrosis factor alpha (TNFalpha)-induced leukocyte recruitment model. Leukocyte adhesion and rolling were examined in pial venules of rat brain by using confocal laser scanning microscopy after labeling leukocytes with rhodamine 6G. Experiments were conducted 4h after TNFalpha injection (0.5microg) in six groups: control, TNFalpha alone, TNFalpha + vehicle of simvastatin, TNFalpha + simvastatin (20mg/kg, 2ml/kg), TNFalpha + vehicle of pravastatin, and TNFalpha + pravastatin (40mg/kg, 2ml/kg)....Continue Reading

References

Nov 1, 1991·Microvascular Research·A VillringerK M Einhäupl
Feb 1, 1990·Nature·J L Goldstein, M S Brown
May 1, 1994·Stroke; a Journal of Cerebral Circulation·U DirnaglA Villringer
Jul 22, 1998·Proceedings of the National Academy of Sciences of the United States of America·M EndresJ K Liao
Sep 3, 1998·The Journal of Biological Chemistry·U Laufs, J K Liao
Feb 6, 1999·Journal of the American College of Cardiology·W H KaesemeyerR W Caldwell
Apr 25, 2000·Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism·M YamadaM A Moskowitz
Dec 16, 2000·The New England Journal of Medicine·A S Brett
Apr 3, 2001·Stroke; a Journal of Cerebral Circulation·S Amin-HanjaniM A Moskowitz
May 22, 2001·European Journal of Vascular and Endovascular Surgery : the Official Journal of the European Society for Vascular Surgery·M JoyceD J Bouchier-Hayes
Jun 5, 2002·Atherosclerosis. Supplements·James K Liao
Oct 16, 2002·Circulation·Diethard PrueferMichael Buerke

❮ Previous
Next ❯

Citations

Oct 21, 2006·Current Opinion in Rheumatology·Masataka Kuwana
Feb 1, 2006·Arthritis and Rheumatism·Aryeh M Abeles, Michael H Pillinger
Jul 28, 2019·QJM : Monthly Journal of the Association of Physicians·Hui-Chen LinNai-Wen Tsai
Apr 27, 2021·Frontiers in Pharmacology·Weilin ChenHonglin Zhu

❮ Previous
Next ❯

Related Feeds

Autoimmune Polyendocrine Syndromes

This feed focuses on a rare genetic condition called Autoimmune Polyendocrine Syndromes, which are characterized by autoantibodies against multiple endocrine organs. This can lead to Type I Diabetes.

Autoimmune Polyendocrinopathies

Autoimmune polyendocrinopathies, also called polyglandular autoimmune syndromes (PGASs), or polyendocrine autoimmune syndromes(PASs), are a heterogeneous group of rare diseases characterized by autoimmune activity against more than one endocrine organ, although non-endocrine organs can be affected. Discover the latest research on autoimmune polyendocrinopathies here.